血清およびグルココルチコイド調節キナーゼ1の病理学的役割が,不良な心室リモデリングに起因する
Saumya Das1, Takeshi Aiba, Michael Rosenberg
1Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Circulation
|September 29, 2012
まとめ
血清およびグルココルチコイド調節キナーゼ-1 (SGK1) は,心不全で活性化され,心機能不全や心律不整が悪化します. SGK1を阻害すると,心臓が保護され,心臓疾患の治療標的として示唆されます.
科学分野:
- 心血管生物学 心血管生物学
- 分子心臓病学 分子心臓病学
- バイオメディカル・リサーチ
背景:
- 心不全は,死亡率と罹病率の重要な原因です.
- 心臓のフォスファティディル・イノシトール3キナーゼ (PI3K) 信号伝達は,心不全で逆説的に活性化されています.
- ダウンストリーム効果因子である血清およびグルココルチコイド調節キナーゼ-1 (SGK1) は,心不全において研究されました.
研究 の 目的:
- 心不全の病原性におけるSGK1の役割を調査する.
- SGK1が心臓病の潜在的治療標的であるかどうかを判断する.
主な方法:
- ネズミのモデルにおける構成的に活性または支配的-負のSGK1の心臓特異的発現を活用した.
- 評価された死亡率,心臓機能,心室不律症,心臓のナトリウムチャネル機能.
- SGK1誘発のプロアリズム効果に対するラノラジンの効果を調査した.
- 血動力学的ストレス後の心筋線維症と心不全に対するSGK1抑制の影響を評価した.
主要な成果:
- 心臓SGK1は,ヒトとネズミの心不全で活性化することが判明しました.
- マウスにおけるSGK1の心臓特異的活性化は,死亡率の増加,心臓機能不全,心室不律を引き起こした.
- SGK1に起因する不律は,心臓のナトリウムチャネルの変化と関連しており,ラノラジンによって逆転した.
- SGK1から保護されたマウスの心臓特異的抑制により,繊維症,心不全,および血動力学的ストレス後のナトリウムチャネル変化からSGK1が保護されます.
結論:
- SGK1は,心不全における有害な心室改造の重要な特徴に必要かつ十分である.
- SGK1は,心臓病の新たな治療標的となる可能性がある.
関連する概念動画
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...